Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

ACLX - Arcellx Inc


IEX Last Trade
68.83
1.350   1.961%

Share volume: 327,101
Last Updated: Fri 30 Aug 2024 10:00:00 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$67.48
1.35
2.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
4%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 10%
Performance
5 Days
-0.92%
1 Month
11.46%
3 Months
31.58%
6 Months
2.11%
1 Year
93.52%
2 Year
299.19%
Key data
Stock price
$68.83
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$30.88 - $75.10
52 WEEK CHANGE
$0.84
MARKET CAP 
3.695 B
YIELD 
N/A
SHARES OUTSTANDING 
53.756 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
BETA 
1.98
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$327,218
AVERAGE 30 VOLUME 
$439,253
Company detail
CEO: Rami Elghandour
Region: US
Website: https://arcellx.com
Employees: 78
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Arcellx Inc. is a clinical-stage biotechnology company. The Company is focused developing controllable cell therapies for the treatment of patients with cancer and other incurable diseases.

Recent news